Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ChemoMetec ASOCSE:CHEMM -2.21%99 Return-on-Tangible-Asset is 29.13% as of Dec. 2025, which is 1% below its 10-year median of 29.45. GuruFocus rates OCSE:CHEMM with a GF Score™ of 99/100 and a GF Value™ of kr552.84 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 855 Medical Devices & Instruments companies, ChemoMetec AS ranks better than 97.66% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. ChemoMetec AS's annualizedNet Income for the quarter that ended in Dec. 2025 was kr188.0 Mil. ChemoMetec AS's average total tangible assets for the quarter that ended in Dec. 2025 was kr645.2 Mil. Therefore, ChemoMetec AS's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was 29.13%.
The historical rank and industry rank for ChemoMetec AS's Return-on-Tangible-Asset or its related term are showing as below:
OCSE:CHEMM'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 11.36 Med: 29.45 Max: 44.24
Current: 28.14
During the past 13 years, ChemoMetec AS's highest Return-on-Tangible-Asset was 44.24%. The lowest was 11.36%. And the median was 29.45%.
OCSE:CHEMM's Return-on-Tangible-Asset is ranked better than 97.66% of 855
companies
in the Medical Devices & Instruments industry
Industry Median: 0.62
vs OCSE:CHEMM: 28.14
ChemoMetec AS (OCSE:CHEMM) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
ChemoMetec AS Return-on-Tangible-Asset Related Terms
ChemoMetec AS Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for ChemoMetec AS's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OCSE:CHEMM vs ABT, SYK, MDT: Return-on-Tangible-Asset Comparison
For the Medical Devices subindustry, ChemoMetec AS's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ChemoMetec AS Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ChemoMetec AS's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where ChemoMetec AS's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of 29.13% mean?
ChemoMetec AS (OCSE:CHEMM) has a Return-on-Tangible-Asset of 29.13% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on ChemoMetec AS and its competitors. This is near median its historical median of 29.45. Over the past decade, ChemoMetec AS's Return-on-Tangible-Asset has ranged from 11.36 to 44.24. According to the industry distribution chart, ChemoMetec AS ranks #20 out of 855 companies in the Medical Devices & Instruments industry, placing it in the top 2.3%.
Is ChemoMetec AS's Return-on-Tangible-Asset too high?
ChemoMetec AS's current Return-on-Tangible-Asset of 29.13% is near median its 10-year median of 29.45. Over the past 10 years, this metric has ranged from a low of 11.36 to a high of 44.24. The Medical Devices & Instruments industry median Return-on-Tangible-Asset is 0.62. ChemoMetec AS's value of 29.13% is 4598.4% above this industry median. Based on the distribution chart, ChemoMetec AS ranks #20 out of 855 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, ChemoMetec AS has a GF Score™ of 99/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ChemoMetec AS's Return-on-Tangible-Asset compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, ChemoMetec AS ranks #20 out of 855 companies for Return-on-Tangible-Asset. This places ChemoMetec AS in the top 2% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 0.62. ChemoMetec AS's value of 29.13% is 4598.4% above this benchmark. Historically, ChemoMetec AS's own Return-on-Tangible-Asset has ranged from 11.36 to 44.24 over the past decade. While the company's 10-year median is 29.45 vs. the industry median of 0.62, ChemoMetec AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.62, based on 855 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ChemoMetec AS's current Return-on-Tangible-Asset of 29.13% is 4598.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on ChemoMetec AS and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ChemoMetec AS's current Return-on-Tangible-Asset is 29.13%, which is near median its own 10-year median of 29.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ChemoMetec AS stock overvalued right now?
Based on GuruFocus' analysis, ChemoMetec AS (OCSE:CHEMM) is currently considered Modestly Undervalued. The stock's GF Value™ is kr552.84, compared to a current price of kr407.00 — trading 26.4% below its estimated fair value. The current Return-on-Tangible-Asset is 29.13%, which is near median its 10-year median of 29.45 and 4598.4% above the Medical Devices & Instruments industry median of 0.62. ChemoMetec AS's overall GF Score™ is 99/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For ChemoMetec AS (OCSE:CHEMM), the current Return-on-Tangible-Asset is 29.13% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ChemoMetec AS (OCSE:CHEMM) Overvalued in 2026?
Based on GuruFocus' analysis, ChemoMetec AS stock appears to be undervalued.
The current stock price of kr407.00 is trading 26.4% below its estimated GF Value™ of kr552.84.
GuruFocus considers ChemoMetec AS to be Modestly Undervalued.
Key valuation signals for OCSE:CHEMM:
Return-on-Tangible-Asset: 29.13% (near median its 10-year median of 29.45)
GF Value™: kr552.84 vs. price of kr407.00 (26.4% below fair value)
Industry Position: 4598.4% above the Medical Devices & Instruments median (#20 of 855)
No single metric tells the full story. See the OCSE:CHEMM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ChemoMetec AS specializes in designing, developing, and producing instruments using patented technology in cell counting and evaluation. It is engaged in the manufacturing and marketing of analytical instruments used for quantitative analysis of cells in liquids. Its applications include Cell Analysis and counting of Mammalian Cells, Yeast Cells, and Sperm Cells. It provides platforms for the determination of viability and cell count of yeast, veterinary semen, mammalian cells, and somatic cells as well as image analysis. It has four segments instruments; consumables; services and others, and the majority of its revenue is generated from the Consumable segment.
99GF Score
Get the complete analysis for OCSE:CHEMM
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCSE:CHEMM has been successfully added to your 
